HBM Holdings Limited (HKG:2142)

Hong Kong · Delayed Price · Currency is HKD

13.43

+0.57 (4.43%)

May 7, 2026, 4:08 PM HKT

54.90% (1Y)

Market Cap	10.75B +106.8%
Revenue (ttm)	1.23B +314.6%
Net Income	710.88M +3,187.7%
EPS	0.86 +2,958.9%
Shares Out	835.56M
PE Ratio	15.02
Forward PE	23.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,813,000
Average Volume	3,317,143
Open	12.92
Previous Close	12.86
Day's Range	12.92 - 13.68
52-Week Range	7.52 - 17.98
Beta	1.40
RSI	51.50
Earnings Date	Aug 27, 2026

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Employees 272

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2142

Full Company Profile

Financial Performance

In 2025, HBM Holdings's revenue was $157.98 million, an increase of 314.63% compared to the previous year's $38.10 million. Earnings were $91.33 million, an increase of 3187.72%.

Financial numbers in USD Financial Statements